Selinexor, Mezigdomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Relapsing / Ineligible for T-Cell-Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results (IMS 2026) - Sep 11, 2026 - Abstract #PA-437; Pres time: Sep 24, 2026; P1/2 | "Three pts relapsed after TCRT (3 cilta-cel; 2 talquetamab; 1 IGM-2644) and 4 after belantamab mafodotin, with 3 pts refractory to B-cell maturation antigen–targeted therapy. For the SMd all-oral combination, TEAEs were consistent with AE profiles for S and M, and no new safety signals were detected. The DLT of G4 neutropenia was manageable with filgrastim and dose reduction. Across all dose levels SMd showed efficacy in pts with heavily pretreated RRMM in whom TCRT had failed or who could not receive TCRT."
Clinical • IO biomarker • P1 data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CCR7 • CRBN • TIGIT • XPO1
|
|
Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results Clifton Mo1; Cristina Gasparetto2; Cristiana Costa2; Andrew J. Cowan3; Tomer Mark4; Yi Chai4; Trinayan Kashyap4; Jessica Katz5; Michael Amatangelo5; Paul G. Richardson1
|